Gene therapy is one of the best treatment
options for most chronic diseases. It involves inserting a functional
copy of a gene into a defective cell. Gene therapy is useful in the
treatment of cancers, inherited disorders, cardiovascular diseases, and
infectious pathogen neurological disorders. Viral or non-viral vector
methods are used in efficient transfer of therapeutic gene into the
target cells. Viral vectors used in gene therapy include adenovirus,
lentivirus, retrovirus, and adeno-associated viral (AAV). Non-viral
vectors generally depend on delivery of plasmid DNA.
Development of quality vectors in terms
of formulation, physical size, cost, and delivery function is quite
challenging. To minimize this problem, manufacturers use various
approaches such as development of cell line culture, current good
manufacturing practices, cell culture system, and expression systems
that are used in the development of vectors. This is projected to boost
the growth of the global viral vectors manufacturing market.
Additionally, increase in the number of gene therapy candidates due to
rapid development of diseases and rise in funding for gene therapies are
expected to fuel the growth of the global viral vectors manufacturing
market. The Alliance for Cancer Gene Therapy (ACGT) is a public charity
foundation in the U.S. which funds for advancement in cancer gene
therapies from laboratory to clinical trials. However, high cost of gene
therapies and possible mutagenesis restrain the market.
The global viral vectors manufacturing
market can be segmented based on type, disease, application, and region.
In terms of type, the global market can be divided into adenoviral
vectors, retroviral vectors, adeno-associated viral vectors, and others.
The retroviral vectors segment dominated the global viral vectors
manufacturing market due to ease of application in major target diseases
such as cancer and genetic disorders. Based on disease, the global
viral vectors manufacturing market can be classified into cancers,
infectious diseases, genetic disorders, and other diseases. The genetic
disorders segment is anticipated to dominate the market due to increase
in research activities on various genetic disorders such as sickle cell
anemia, hemophilia A and B, and Huntington’s disease, and a strong gene
therapy pipeline in the last phase of drug development. In terms of
application, the global market can be bifurcated into gene therapy and
vaccinology. The gene therapy segment is expected to account for the
largest share of the market due to increase in the number of gene
therapy clinical trials conducted for chronic diseases such as cancer,
cardiovascular diseases, and neurodegenerative diseases globally.
Geographically, the global viral vectors
manufacturing market can be segmented into North America, Europe, Latin
America, Asia Pacific, and Middle East & Africa. Each region can be
divide into specific countries/sub-regions such as the U.S., Canada, the
U.K., Germany, Brazil, China, India, and GCC Countries. North America
dominated the global viral vectors manufacturing market because of
increase in research activities, large number of regenerative medicine
companies, rise in prevalence of target diseases, and availability of
funds. Asia Pacific is expected to be the most attractive market during
the forecast period due to increase in health awareness and demand for
advanced medical technology.
Key players operating in the global viral
vectors manufacturing market are Lonza, Merck, Oxford BioMedica, CGT
Catapult, Cobra Biologics, uniQure, FUJIFILM Diosynth Biotechnologies,
Kaneka Eurogentec, and Spark Therapeutics, among others. These players
adopt various strategies such as collaborations, agreements,
partnerships, and launch of new products to gain competitive advantage
in the market.
No comments:
Post a Comment